<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2307">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508439</url>
  </required_header>
  <id_info>
    <org_study_id>NR-CEI-HRAEI-19-2020</org_study_id>
    <nct_id>NCT04508439</nct_id>
  </id_info>
  <brief_title>Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection</brief_title>
  <official_title>Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Regional de Alta especialidad de Ixtapaluca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Regional de Alta especialidad de Ixtapaluca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Viral infections provoke the systemic inflammatory response and cause an imbalance between
      the procoagulant and anticoagulant homeostatic mechanisms. Multiple pathogenic mechanisms are
      involved, including endothelial dysfunction, increased von Willebrand factor, Toll receptor
      activation, and tissue factor pathway activation. D-dimer levels greater than 1000 ng / mL
      are associated with an 18-fold increased risk of mortality. In this context, many patients
      may require prophylaxis or antithrombotic treatment with low molecular weight heparins.
      Currently, there is no validated scheme on the dose and timing of the use of antithrombotic
      drugs.

      The study aims to identify the effect of two anticoagulant strategies (prophylactic and
      therapeutic) on the progression to ventilatory support or death in patients with COVID-19
      infection who require hospital care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized clinical trial in patients with a confirmed infection by COVID-19 who require
      hospital treatment and subsequent ambulatory surveillance.

      Study population. Patients with a diagnosis by PCR of COVID 19, over 18 years of age from the
      High Specialty Hospital of Ixtapaluca, who meet the inclusion criteria.

      Statistic analysis. The student's T-test was carried out to identify the difference in the
      means of the quantitative variables between the groups. A value of P ≤ 0.05, 95% CI will be
      considered significant. For the hypothesis test, the chi-square test will be performed,
      considering a p≤ 0.05, 95% CI value to be significant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Initially they will be randomized into two blocks, the first based on prophylactic Enoxaparin (Numbers 1 to 64) and the second (Numbers 65 to 128) will be assigned to the Enoxaparin therapeutic regimen arm at doses of 1mg / kg/dose twice up to date
During hospitalization, the clinical evolution will be evaluated according to the requirements of mechanical ventilation, the reduction in D-Dimer levels and the clinical outcome (discharge or death).
Those patients who are discharged will be Randomized in two following treatment arms
The allocation of patients in the outpatient stage will be carried out randomly 1: 1 to receive Rivaroxaban 10mg PO every 24hrs or only clinical follow-up.
Follow-up of adverse events will be carried out in the Hematology outpatient clinic with a first consultation 15 days after discharge and a second consultation 30 days after discharge. With dimer D, ferritin, protein C, blood count, ESR and on day 30 with CAT.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>low molecular weight heparin (enoxaparin) and ventilatory support time</measure>
    <time_frame>30 days</time_frame>
    <description>Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on ventilatory support time in patients requiring hospital care for COVID-19 infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>thrombotic complications and Rivaroxaban</measure>
    <time_frame>30 days</time_frame>
    <description>To compare oral anticoagulation therapy by administering Rivaroxaban 10mg PO every 24 hours on early thrombotic complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>low molecular weight heparin (enoxaparin) and length of hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the length of hospital stay in patients requiring hospital care for COVID-19 infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>low molecular weight heparin (enoxaparin) and mortality rate</measure>
    <time_frame>30 days</time_frame>
    <description>Identify the benefit of different doses of low molecular weight heparin (enoxaparin) over mortality rate in patients requiring hospital care for COVID-19 infection.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Covid19</condition>
  <condition>Pneumonia</condition>
  <condition>Coagulation Disorder</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Prophylactic enexaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoxaparin dose of 1mg / kg / dose twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin dose of 1mg / kg / dose daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.</description>
    <arm_group_label>Prophylactic enexaparin</arm_group_label>
    <arm_group_label>Therapeutic Enoxaparin</arm_group_label>
    <other_name>low molecular weight heparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of COVID-19 infection confirmed by polymerase chain reaction
             test (RQ-PCR) requiring hospital care for the administration of supplemental oxygen

        Exclusion Criteria:

          -  Patients with life expectancy less than 48hrs

          -  Patients who require ventilatory support upon admission

          -  Age over 75 years or with a history of atrial fibrillation

          -  History of venous or arterial thrombosis

          -  Severe neurological impairment

          -  Absence of a primary caregiver to supervise the administration of medication

          -  History of cerebral hemorrhage

          -  History of previous use of oral anticoagulants

          -  History of major surgery 30 days prior to admission

          -  Uncontrolled systemic arterial hypertension

          -  KDIGO stage III chronic kidney disease or less

          -  Hemodialysis or peritoneal dialysis treatment

          -  History of active or inactive cancer

          -  Pregnant or postpartum patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Omar Ramos-Peñafiel, MD, PhD</last_name>
    <phone>+525523351588</phone>
    <email>christian.ramos.penafiel@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Regional de Alta Especialidad de Ixtapaluca</name>
      <address>
        <city>Mexico City</city>
        <state>Ixtapaluca</state>
        <zip>56530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar O Ramos-Peñafiel</last_name>
      <phone>5523351588</phone>
      <email>christian.ramos.penafiel@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>August 8, 2020</last_update_submitted>
  <last_update_submitted_qc>August 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Regional de Alta especialidad de Ixtapaluca</investigator_affiliation>
    <investigator_full_name>Omar Ramos-Peñafiel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>Mortality</keyword>
  <keyword>anticoagulants</keyword>
  <keyword>Deep venous thrombosis</keyword>
  <keyword>Pulmonary embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

